Compare MPB & ARCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MPB | ARCT |
|---|---|---|
| Founded | 1868 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 827.5M | 163.4M |
| IPO Year | 1996 | 2019 |
| Metric | MPB | ARCT |
|---|---|---|
| Price | $36.85 | $16.05 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 10 |
| Target Price | ★ $37.00 | $24.11 |
| AVG Volume (30 Days) | 70.5K | ★ 1.3M |
| Earning Date | 04-21-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.66% | N/A |
| EPS Growth | N/A | ★ 20.00 |
| EPS | ★ 1.22 | N/A |
| Revenue | N/A | ★ $82,031,000.00 |
| Revenue This Year | $30.95 | N/A |
| Revenue Next Year | $9.45 | $12.77 |
| P/E Ratio | $30.16 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $26.56 | $5.50 |
| 52 Week High | $39.15 | $24.14 |
| Indicator | MPB | ARCT |
|---|---|---|
| Relative Strength Index (RSI) | 46.02 | 63.50 |
| Support Level | $35.87 | $6.47 |
| Resistance Level | $37.37 | $17.75 |
| Average True Range (ATR) | 0.75 | 1.42 |
| MACD | -0.04 | -0.18 |
| Stochastic Oscillator | 47.06 | 62.40 |
Mid Penn Bancorp Inc is a financial holding company, providing various banking and financial products and services through its subsidiaries. These products and services mainly include consumer banking products, including secure checking and savings accounts, mobile banking, agricultural loans, construction financing, mortgages, home equity loans and lines of credit, credit cards, and more. Additionally, the Group offers trust services, insurance products, wealth management, and private banking services. The Group caters to individuals, partnerships, non-profit organizations, and corporations through its retail banking offices located throughout Pennsylvania, with a minor portion in New Jersey.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.